Cure My Disease

Don't miss your cure!

 Log in / Sign up

Leukemia drug Asciminib's Long-Term safety tracked in ongoing study

NCT ID NCT04877522

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows people with chronic myeloid leukemia (CML) who have already benefited from the drug asciminib in earlier Novartis trials. Researchers want to see how safe the drug is over the long term. About 347 participants will continue taking asciminib or other similar drugs and be monitored for side effects. No new treatment is being tested—this is about checking safety for those already on the medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Asciminib (also known as ABL001), imatinib, nilotinib, bosutinib, dasatinib

What this could lead to

If successful, this study will confirm that long-term use of asciminib is safe for controlling chronic myeloid leukemia.

What could go wrong

This is an observational roll-over study, not a test of a new treatment. It only includes patients already benefiting, so results may not apply to everyone. Side effects are still possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) blast phase chronic myelogenous leukemia, BCR-ABL1 positive chronic myelogenous leukemia, BCR-ABL1 positive leukemia, acute lymphocytic, susceptibility to, 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Myeloproliferative Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOGENOUS LEUKEMIA LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Medical College of Wisconsin

    RECRUITING

    Milwaukee, Wisconsin, 53226, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Memorial Sloan Kettering

    RECRUITING

    New York, New York, 10017, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Michigan Med University of Michigan

    RECRUITING

    Ann Arbor, Michigan, 48109 5271, United States

    Contact Email: •••••@•••••

    Contact

  • Novartis Investigative Site

    RECRUITING

    CABA, Buenos Aires, C1221ADC, Argentina

  • Novartis Investigative Site

    RECRUITING

    Capital Federal, C1114AAN, Argentina

  • Novartis Investigative Site

    RECRUITING

    Graz, 8036, Austria

  • Novartis Investigative Site

    RECRUITING

    Vienna, 1140, Austria

  • Novartis Investigative Site

    COMPLETED

    Rio de Janeiro, Rio de Janeiro, 20211-030, Brazil

  • Novartis Investigative Site

    COMPLETED

    São Paulo, São Paulo, 05403 000, Brazil

  • Novartis Investigative Site

    COMPLETED

    São Paulo, São Paulo, 08270-070, Brazil

  • Novartis Investigative Site

    RECRUITING

    Varna, 9000, Bulgaria

  • Novartis Investigative Site

    RECRUITING

    Montreal, Quebec, H1T 2M4, Canada

  • Novartis Investigative Site

    RECRUITING

    Chongqing, Chongqing Municipality, 400010, China

  • Novartis Investigative Site

    RECRUITING

    Guangzhou, Guangdong, 510515, China

  • Novartis Investigative Site

    RECRUITING

    Zhengzhou, Henan, 450008, China

  • Novartis Investigative Site

    RECRUITING

    Wuhan, Hubei, 430022, China

  • Novartis Investigative Site

    RECRUITING

    Changchun, Jilin, 130021, China

  • Novartis Investigative Site

    RECRUITING

    Xian, Shanxi, 710004, China

  • Novartis Investigative Site

    COMPLETED

    Chengdu, Sichuan, 610041, China

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Beijing, 100044, China

  • Novartis Investigative Site

    RECRUITING

    Beijing, 100730, China

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Shanghai, 200025, China

  • Novartis Investigative Site

    RECRUITING

    Shenyang, 110004, China

  • Novartis Investigative Site

    RECRUITING

    Tianjin, 300020, China

  • Novartis Investigative Site

    RECRUITING

    Ostrava, Poruba, 708 52, Czechia

  • Novartis Investigative Site

    RECRUITING

    Brno, 625 00, Czechia

  • Novartis Investigative Site

    COMPLETED

    Copenhagen, DK-2100, Denmark

  • Novartis Investigative Site

    RECRUITING

    Bordeaux, 33076, France

  • Novartis Investigative Site

    RECRUITING

    Lyon, 69373, France

  • Novartis Investigative Site

    RECRUITING

    Marseille, 13273, France

  • Novartis Investigative Site

    RECRUITING

    Nantes, 44093, France

  • Novartis Investigative Site

    RECRUITING

    Paris, 75475, France

  • Novartis Investigative Site

    RECRUITING

    Vandœuvre-lès-Nancy, 54511, France

  • Novartis Investigative Site

    RECRUITING

    Frankfurt am Main, Hesse, 60590, Germany

  • Novartis Investigative Site

    RECRUITING

    Jena, Thuringia, 07740, Germany

  • Novartis Investigative Site

    RECRUITING

    Berlin, 13353, Germany

  • Novartis Investigative Site

    RECRUITING

    Kiel, 24116, Germany

  • Novartis Investigative Site

    RECRUITING

    Milan, MI, 20162, Italy

  • Novartis Investigative Site

    RECRUITING

    Roma, RM, 00161, Italy

  • Novartis Investigative Site

    COMPLETED

    Naples, 80131, Italy

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Kobe, Hyōgo, 650-0017, Japan

  • Novartis Investigative Site

    COMPLETED

    Beirut, 113-0236, Lebanon

  • Novartis Investigative Site

    RECRUITING

    George Town, Pulau Pinang, 10450, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Johor Bahru, 80100, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Kuala Selangor, 68000, Malaysia

  • Novartis Investigative Site

    RECRUITING

    Monterrey, Nuevo León, 64460, Mexico

  • Novartis Investigative Site

    RECRUITING

    Khoudh, 123, Oman

  • Novartis Investigative Site

    RECRUITING

    Katowice, 40-519, Poland

  • Novartis Investigative Site

    COMPLETED

    Krakow, 30-688, Poland

  • Novartis Investigative Site

    RECRUITING

    Warsaw, 00-791, Poland

  • Novartis Investigative Site

    COMPLETED

    Wroclaw, 50 367, Poland

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Lisbon, 1099-023, Portugal

  • Novartis Investigative Site

    RECRUITING

    Porto, 4200-072, Portugal

  • Novartis Investigative Site

    COMPLETED

    Timișoara, 300079, Romania

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Moscow, 125167, Russia

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Moscow, 125284, Russia

  • Novartis Investigative Site

    RECRUITING

    Saint Petersburg, 191024, Russia

  • Novartis Investigative Site

    RECRUITING

    Saint Petersburg, 197341, Russia

  • Novartis Investigative Site

    COMPLETED

    Riyadh, 11211, Saudi Arabia

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Singapore, 169608, Singapore

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Uijeongbu-si, Gyeonggi-do, 11759, South Korea

  • Novartis Investigative Site

    COMPLETED

    Busan, 49201, South Korea

  • Novartis Investigative Site

    COMPLETED

    Jeollanam, 519763, South Korea

  • Novartis Investigative Site

    RECRUITING

    Seoul, 03080, South Korea

  • Novartis Investigative Site

    RECRUITING

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    RECRUITING

    Badalona, Barcelona, 08916, Spain

  • Novartis Investigative Site

    RECRUITING

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    RECRUITING

    Bilbao, Bizkaia, 48013, Spain

  • Novartis Investigative Site

    RECRUITING

    Santa Cruz, Santa Cruz De Tenerife, 38009, Spain

  • Novartis Investigative Site

    RECRUITING

    Barcelona, 08035, Spain

  • Novartis Investigative Site

    COMPLETED

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28006, Spain

  • Novartis Investigative Site

    COMPLETED

    Madrid, 28034, Spain

  • Novartis Investigative Site

    RECRUITING

    Madrid, 28041, Spain

  • Novartis Investigative Site

    RECRUITING

    Seville, 41009, Spain

  • Novartis Investigative Site

    RECRUITING

    Valencia, 46026, Spain

  • Novartis Investigative Site

    ACTIVE_NOT_RECRUITING

    Taoyuan, 33305, Taiwan

  • Novartis Investigative Site

    RECRUITING

    Samsun, Atakum, 55200, Turkey (Türkiye)

  • Novartis Investigative Site

    RECRUITING

    London, W12 0HS, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Oxford, OX3 7LE, United Kingdom

  • Novartis Investigative Site

    RECRUITING

    Hanoi, 100000, Vietnam

  • Novartis Investigative Site

    RECRUITING

    Ho Chi Minh City, 70000, Vietnam

  • Oregon Health Sciences University

    ACTIVE_NOT_RECRUITING

    Portland, Oregon, 97239, United States

  • Texas Oncology

    RECRUITING

    Dallas, Texas, 75251, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Uni Of TX MD Anderson Cancer Cntr

    RECRUITING

    Houston, Texas, 77030, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••